An interventional study of Splenectomy and Control in Acute Necrotizing Pancreatitis and Portal Hypertension, sponsored by Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-23.
Sponsored by Zhejiang University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Pancreatitis, Acute Necrotizing with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Pancreatitis, Acute Necrotizing · China.
Among the 17 studies in Pancreatitis, Acute Necrotizing with a site in China, this one is the 10th largest by planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2025, is one of 8 with no phase, and was the 15th registered.
75 studies on the registry are indexed under Pancreatitis, Acute Necrotizing; 20 are open to participants now.
Browse Pancreatitis, Acute Necrotizing studies →6 of the 17 studies in Pancreatitis, Acute Necrotizing with a site in China are open now. Recruiting first, the newest first:
Chunling Jiang · Sites in China
Ages 18+
First People's Hospital of Hangzhou · Sites in China
Ages 18+
West China Hospital · Sites in China
Ages 18+
Almazov National Medical Research Centre · Sites in China, Russia
Ages 18+
The First Affiliated Hospital of Nanchang University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 12 Pancreatitis, Acute Necrotizing studies recruiting now, 9 (75%) set no upper age limit and 3 (25%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 66 is close to the median of 70 across 47 interventional studies indexed under Pancreatitis, Acute Necrotizing.
Median enrollment 135 across the 14 interventional studies, 200 across the 3 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 17 has an industry lead sponsor. The 10 most frequent:
Zhejiang University is the lead sponsor of 357 studies on the registry; 167 are open to participants now.
Zhejiang University has 1 study filed under Pancreatitis, Acute Necrotizing — fewer than ten, so there is no comparison to draw.
4 of the studies in Pancreatitis, Acute Necrotizing with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07093996Almazov National Medical Research CentreEndoscopic Pancreatic Duct Stent Placement Versus Conventional Approach in the Treatment of Early Phase Acute Pancreatitis | 2026-12-01 |
| NCT07201246West China HospitalOrgan Dysfunction Changes in Acute Necrotizing Pancreatitis Patients With Sepsis Following Open Necrosectomy | 2026-12-30 |
| NCT06380842Chunling JiangOrgan Dysfunction Change in Acute Necrotizing Pancreatitis Patients With Sepsis After Open Necrosectomy | 2026-12-30 |
| NCT07080697Zhejiang UniversityA Study to Evaluate Splenectomy on Debridement for Acute Necrotizing Pancreatitis With Pancreatic Sinistral Portal Hypertension | 2027-02-28 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies in Pancreatitis, Acute Necrotizing with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a prospective, single-center, randomized controlled trial focusing on patients with acute necrotizing pancreatitis (ANP) complicated by pancreatic sinistral portal hypertension (PSPH). The study aims to study the impact of total splenectomy on the debridement efficacy, perioperative recovery, and prognosis of patients with ANP complicated by PSPH.
This study is a prospective, single-center, randomized controlled trial focusing on patients with acute necrotizing pancreatitis (ANP) complicated by pancreatic sinistral portal hypertension (PSPH). A total of 66 participants are planned to be enrolled. The study aims to compare the outcomes of two surgical approaches: open debridement combined with distal pancreatectomy and total splenectomy versus open debridementalone. The objective is to observe the impact of total splenectomy on the debridement efficacy, perioperative recovery, and prognosis of patients with ANP complicated by PSPH. The primary observational indicators include postoperative length of hospital stay, postoperative cost, postoperative life quality, and the alleviation of PSPH. Secondary observational indicators encompass the number of unplanned reoperations, postoperative infection control, postoperative irrigation volume, postoperative antibiotic consumption, and postoperative platelet count change. The study will be carried out in accordance with the protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Open Debridement combined with Distal Pancreatectomy and Total Splenectomy
Procedure: Splenectomy
Open Debridement alone
Procedure: Control
Open Debridement combined with distal pancreatectomy and total splenectomy
Open Debridement alone
Length of hospital stay after debridement
The total length of hospital stay after debridement, including readmissions.
Time frame: From enrollment of the first subject to completion of follow-up of the last subject (up to 5 years)
Degree of pancreatic sinistral portal hypertension
The degree of pancreatic sinistral portal hypertension after intervention
Time frame: From enrollment of the first subject to completion of follow-up of the last subject (up to 5 years)
Intensive Care Unit stay post Operation
Time frame: Perioperative
Pancreatic Fistula
The rate of pancreatic fistula
Time frame: Perioperative
Number of Draining Tube when Discharged
Time frame: Perioperative
Time of all draining tubes removal
Time frame: From enrollment of the first subject to completion of follow-up of the last subject (up to 5 years)
Cost post debridement in the first hospitalization
Time frame: Perioperative
Number of unplanned re-admissions
Time frame: From enrollment of the first subject to completion of follow-up of the last subject (up to 5 years)
Number of unplanned operations
Time frame: From enrollment of the first subject to completion of follow-up of the last subject (up to 5 years)
Number of percutaneous drainage after debridement
Time frame: From enrollment of the first subject to completion of follow-up of the last subject (up to 5 years)
Antibiotic use after treatment
Time frame: Perioperative
Abdominal lavage
Abdominal lavage volume after treatment
Time frame: Perioperative
Life quality one year after treatment
Life quality one year after treatment was judged by the Short-Form 36 Health Survey (SF-36), encompassing both physical and mental health across eight dimensions: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The minimum value is 0%, the maximum value is 100%, and a higher score means a better life quality.
Time frame: Within one year after the last subject was treated
Platelet number after debridement
Time frame: Within one year after the last subject was treated
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2025; primary completion for Feb 2027, 18 months later.
Of 20 interventional studies with no phase under Pancreatitis, Acute Necrotizing, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 36. This study's planned 18 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pancreatitis, Acute Necrotizing →